Rheumatology Advance Access published December 11, First-line DMARD choice in early rheumatoid arthritis do prognostic factors play a role?
|
|
- Angelica Hawkins
- 5 years ago
- Views:
Transcription
1 Rheumatology Advance Access published December 11, 2009 RHEUMATOLOGY Concise report First-line DMARD choice in early rheumatoid arthritis do prognostic factors play a role? doi: /rheumatology/kep389 Satish M. Rachapalli 1, Richard Williams 2, David A. Walsh 3, Adam Young 4, Patrick D. W. Kiely 5 and Ernest H. Choy 1 on behalf of the Early Rheumatoid Arthritis Network (ERAN) Abstract Objective. To examine if prognostic factors predict the choice of first DMARD for patients with RA. Methods. Details of 616 patients with early RA were collected from 16 centres in the UK Early Rheumatoid Arthritis Network (ERAN). Logistic regression was used to identify whether HAQ score, swollen joint count (SJC), nodules, RF, ESR, CRP and erosions on radiographs were associated with the choice of first DMARD treatment. Results. Of 616 patients, 547 (88%) were started on a DMARD, 253 (46%) on MTX, 230 (42%) on SSZ, 47 (9%) on other DMARD monotherapies and 17 (3%) on combination DMARD therapy (CoT). SSZ was started less frequently in patients with positive RF (P = 0.018; OR 0.59; 95% CI 0.38, 0.91) and high SJC (P = 0.02; OR 0.95; 95% CI 0.91, 0.99). MTX was favoured in patients with high SJC (P = 0.002; OR 1.07; 95% CI 1.02, 1.11). Non-prescription of DMARDs was associated with old age (P = 0.02; OR 0.98; 95% CI 0.96, 0.99) and low HAQ score (P = 0.009; OR 0.80; 95% CI 0.68, 0.95). None of the variables predicted CoT. All other variables and the hospital where the patient was treated were not independently associated with the choice of DMARD. Conclusions. When choosing DMARD monotherapy in early RA, rheumatologists in ERAN seem to preferentially prescribe MTX for patients with a poor prognosis and SSZ for patients with good prognosis. No DMARDs were used in older patients or in those with a low HAQ. Key words: Rheumatoid arthritis, DMARD choice, Prognostic factors. Introduction RA is an inflammatory arthritis characterized by synovial tissue inflammation that leads to structural damage and disability. There are several treatment options available, which include glucocorticoids, DMARDs and biologics given alone as monotherapy or in a variety of combinations. Recent evidence has shown that early treatment is important in reducing the rate of progression of erosions 1 Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, King s College London, London, 2 Department of Rheumatology, Hereford County Hospital NHS Trust, Hereford, 3 Academic Rheumatology, University of Nottingham, Nottingham, 4 St Albans City Hospital and 5 Department of Rheumatology, St George s Healthcare NHS Trust, London, UK. Submitted 19 May 2009; revised version accepted 21 October Correspondence to: Ernest H. Choy, Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, Weston Education Centre, King s College London, Cutcombe Road, London SE5 9RJ, UK. satishmohanreddy@yahoo.com and decreasing disability [1 3]. There is no uniform agreement among rheumatologists on the best first-line DMARD in early RA, and there is considerable inter-individual variation in drug prescription [4]. Patients with early RA have a variable prognosis, and current guidelines recommend more intensive treatment for patients who are expected to have a worse prognosis [5]. Previous studies in early RA have identified important prognostic factors [6]. Risk factors for radiographic damage include positive RF, presence of anti-ccp antibodies and features of strong disease activity, such as a high swollen joint count (SJC) or CRP at onset. Predictors indicative of disability in early RA include RF positivity and a raised HAQ score and erosive disease at diagnosis. While these observations are derived from outcomes in population studies, it is unknown whether the presence or absence of any of these predictors of prognosis influences the choice of DMARD treatment in current rheumatological practice. CLINICAL SCIENCE! The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org 1
2 Satish M. Rachapalli et al. The Early Rheumatoid Arthritis Network (ERAN) is a group of centres in the UK and Eire with an interest in treatment and outcome in patients with early RA. A standardized dataset including demographic, comorbidity, disease activity and outcome data is collected prospectively on newly diagnosed RA patients at first presentation and regularly thereafter. The choice of treatment and model of care (i.e. follow-up frequency, thresholds to escalate therapy and access to the multidisciplinary team) is left entirely to the discretion of the individual centres. Participating centres are distributed across the UK and Eire, and may be more representative of current clinical practice than single centre studies. We have utilized the ERAN database to examine whether any of the prognostic factors described above are associated with choice of first DMARD prescribed for patients with early RA. Patients and methods ERAN registry for early RA An inception cohort of 616 patients with RA was identified, recruited in 16 ERAN centres between 2004 and Patients are enrolled in the ERAN registry if they meet the following inclusion criteria: (i) symptom duration <12 months at the time of presentation; and (ii) diagnosed as having RA by a consultant rheumatologist (fulfillment of the ACR 1987 diagnostic criteria is not required). The study was approved by the Trent Research Ethics Committee (REC) and written consent was obtained. Clinical and laboratory assessments Standardized case report forms are completed at first presentation, 3 6 months, 1 year and annually thereafter. Details recorded include centre number, age and sex of the patients, initial DMARD used, presence of RF, erosions on radiographs, presence of nodules, SJC and tender joint count (TJC), ESR, 28 joint disease activity (DAS28) score, CRP and HAQ score. All the observations were recorded locally and source data verification was undertaken by an experienced nurse practitioner who visited each centre regularly. Use of combination DMARD therapy as first-line treatment is defined if the patient is started on two or more DMARDs simultaneously or within the first 3 months of first DMARD use. Statistical analysis Characteristics of patients treated with MTX, SSZ and combination therapy (CoT) or no DMARD at all were compared. Predictors of DMARD choice were determined by logistic regression and expressed as odds ratios (ORs) and 95% CIs. Calculations were made using SPSS version 17 software (SPSS, Chicago, IL, USA). Results Demographics and other baseline characteristics of the study group A total of 616 patients were diagnosed as having early RA during this period. Demographic features, clinical features TABLE 1 Demographic, clinical and laboratory characteristics and disease activity scores Characteristics Age, mean (range), years 56 (19 106) Females, n (%) 425 (69%) Positive RF, a n (%) 308 (50%) Presence of erosions, a n (%) 160 (26%) SJC, b mean (range) 6 (0 57) TJC, b mean (range) 8 (0 57) ESR, mean (range), mm/h b 31 (1 124) CRP, mean (range), mg/l b 25 (0 248) HAQ score, b mean (range) 1.1 (0 3) DAS28, b mean (range) 4.7 ( ) a Presence or absence of RF and erosions was not recorded in 87 and 60 patients, respectively. b SJC was recorded in 615 patients, TJC in 614, ESR in 549, CRP in 370, HAQ score in 603 and DAS in 472. and disease activity scores including DAS28 and HAQ score are shown in Table 1. DMARD choice Out of 616 patients, 547 (88%) were started on a DMARD; 253 (46%) of these patients were started on MTX as monotherapy, 230 (42%) on SSZ as monotherapy, 17 (3%) on CoT and the remaining 47 (9%) on other DMARDs as monotherapy. Association of specific DMARDs with prognostic factors SSZ was started less frequently in patients with positive RF (P = 0.018; OR 0.59; 95% CI 0.38, 0.91) and high SJC (P = 0.02; OR 0.95; 95% CI 0.91, 0.99). MTX was favoured in patients with high SJC (P = 0.002; OR 1.07; 95% CI 1.02, 1.11). Non-prescription of DMARDs was associated with old age (P = 0.02; OR 0.98; 95% CI 0.96, 0.99) and low HAQ score (P = 0.009; OR 0.80; 95% CI 0.68, 0.95) (Table 2). The R 2 was None of the variables predicted CoT, but the number of patients in this group was very small. Presence or absence of all the remaining prognostic factors and the hospital where the patient was treated had no significant association with first DMARD choice. Discussion In this cohort of 616 newly diagnosed patients from ERAN, the majority (88%) were treated first with DMARD monotherapy; MTX in 46% and SSZ in 42%. We found that patients with the recognized poor prognostic factor of a high SJC were given MTX significantly more frequently, whereas those with the good prognostic factors of a negative RF and low SJC were significantly more likely to receive SSZ. We did not find any significant variation in practice between different centres from where the patients were recruited. Our results show that 12% of the patients with early RA were not started on a DMARD, 2
3 First line DMARD choice in early RA TABLE 2 Association of DMARD prescription with prognostic factors Prognostic factors P-value OR (95% CI) SSZ SJC a (0.909, 0.992) TJC (0.97, 1.028) HAQ (0.801, 1.08) ESR (0.999, 1.001) CRP (0.999, 1) DAS (0.997, 1.009) Age (0.977, 1.004) Erosions (0.499, 1.158) RF a (0.38, 0.912) Nodules (0.517, 2.006) Sex (0.475, 1.116) MTX SJC a (1.025, 1.112) TJC (0.962, 1.018) HAQ (0.849, 1.12) ESR (0.999, 1.001) CRP (1, 1.001) DAS (0.992, 1.005) Sex (0.816, 1.859) Age (0.982, 1.008) Erosions (0.564, 1.297) RF (0.885, 2.11) Nodules (0.544, 2.016) No DMARD SJC (0.947, 1.062) TJC (0.949, 1.021) HAQ a (0.68, 0.947) ESR (0.999, 1.002) CRP (1, 1.001) DAS (0.987, 1.004) Sex (0.637, 2.253) Age a (0.956, 0.996) Erosions (0.334, 1.319) RF (0.528, 2.018) Nodules (0.522, 3.442) a Significant association. and this option was significantly more likely in those with good physical function (low HAQ) and old age. Only a small percentage of patients were given first-line CoT, in spite of the evidence that combination DMARD therapy is superior to monotherapy when treating some groups of patients with active RA [7 10]. These findings are similar to other recent observational studies from the European Union, which showed that MTX is used as a single therapy in a significantly higher proportion than other DMARDs [11, 12]. A similar trend is also noted in the UK, where MTX has displaced other DMARDs, especially SSZ, as agent of first choice [13]. This might be due to a variety of reasons. MTX is perceived to have advantages over other DMARDs, and in a US survey >90% of rheumatologists rated MTX as good or excellent at 1 year [14]. It is well tolerated long term [11] and adherence over time compares favourably with SSZ and HCQ, particularly with respect to withdrawals due to inefficacy [15, 16]. There is also evidence that MTX is more efficacious than SSZ in suppressing the progression of erosions [17]. Finally, non-mtx DMARDs have less impact on important comorbidities such as cardiovascular disease [18]. Although MTX is the most favoured drug, our findings showed that SSZ is still the first-choice DMARD in a large proportion of patients. This might be due to several factors. One is an assumption by some rheumatologists that SSZ is safer than MTX. Other factors favouring SSZ might include the need for less intensive monitoring compared with MTX, its safety in pregnancy and relative hepatic safety compared with MTX or LEF in patients who are not willing to reduce alcohol consumption. Our findings suggest that in addition to these various practical, pragmatic and hypothetical advantages of MTX and SSZ in different situations, some prognostic factors were significantly associated with first-line choice of SSZ or MTX. This has also been noted in other studies, which report that patients with high disease activity were given MTX therapy more often than other DMARDs, whereas those with low activity were more likely to receive SSZ [19]. The SJC stands out in our study as the most predictive factor in the choice of first-line DMARD. Fautrel et al. [20] report predictors of second-line DMARD use (after inadequate response for MTX) among French rheumatologists, based on hypothetical vignettes. Interestingly, they also found that SJC was more predictive of DMARD choice than DAS28, implying that rheumatologists are more influenced in routine practice by this clinical finding than by the composite DAS28 index and its other components. A limitation of our study is an inability to determine whether decisions about DMARD prescription occur after a conscious analysis of factors based on their prognostic value or whether they are made by a subconscious process using experience, perhaps given the limitations of busy clinical schedules and the complexities of individual cases. Given the pattern that has emerged from our group of 16 geographically distant centres, it would be of interest to determine this in a further study. In summary, our findings from a large UK inception cohort of patients with newly diagnosed RA suggest that some prognostic factors are influencing the choice of first-line therapy with MTX or SSZ, or the decision not to use a DMARD at all. Our findings support a general impression of MTX being more potent than SSZ and provide evidence that MTX is chosen preferentially over SSZ for patients who are perceived to have more aggressive disease. Rheumatology key messages. MTX and SSZ are the most favoured DMARDs in early RA.. Patients with high SJC are given MTX more frequently.. Only a small percentage of patients with early RA are started on combination therapy. 3
4 Satish M. Rachapalli et al. Acknowledgements The authors thank Cathy Mayes (St Albans) for data handling and management of the ERAN database. The following rheumatologists and nurse specialists contributed data for analysis in this study: Marwan Bukhari and Bronwen Evans (Department of Rheumatology, Lancaster Royal Infirmary); Shane Clarke and Belinda Williams (Department of Rheumatology, Weston Super Mare General Hospital); Amanda Coulson and Suzanne Morris (Department of Rheumatology, Withybush General Hospital); Paul Creamer and Julie Taylor (Department of Rheumatology, Southmead Hospital); Joel David and Maureen Cox (Department of Rheumatology, Nuffield Orthopaedic Centre); Joseph Devlin and Ciaron Duffey (Department of Rheumatology, Regional Hospital); Ciaran Dunne and Lindsey Hawley (Department of Rheumatology, Christchurch Hospital); Andrew Hassell and Michele Kirwan, (Staffordshire Rheumatology Centre, Haywood Hospital); Tom Palferman and Louise Jones (Department of Rheumatology, Yeovil District Hospital); Peter Prouse and Sheryl Andrews (Department of Rheumatology, North Hampshire Hospital); David Walsh and Debbie Wilson (Department of Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Kings Mill Hospital); Michael Webley and Jackie Hall (Department of Rheumatology, Stoke Mandeville Hospital); Richard Williams and Karina Blunn (Department of Rheumatology, County Hospital); and Ann Seymour (Department of Rheumatology, St Albans City Hospital). Funding: ERAN has received funding from Wyeth Pharmaceuticals and the Healthcare Commission. E.H.C. acknowledges financial support from the Department of Health via the National Institutes for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy s and St Thomas NHS Foundation Trust in partnership with King s College London and King s College Hospital NHS Foundation Trust. Disclosure statement: E.H.C. has received research grants and honoraria for advisory boards, consultancy and speaker bureaus from Abbott Laboratories, Allergan, Boehringer Ingelheim, Chelsea Therapeutics, Eli Lilly, GSK, Jazz Pharmaceuticals, Merrimack Pharmaceutical, MSD, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, UCB Celltech and Wyeth. All other authors have declared no conflicts of interest. References 1 Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43: Lard LR, Visser H, Speyer I et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111: Mottonen T, Hannonen P, Korpela M et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46: Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and long term effectiveness. J Rheumatol 1995;22: Saag KG, Teng GG, Patkay NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: Emery P, Breedveld FC, Dougados M et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61: O Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334: Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353: Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350: Choy EH. Two is better than one? Combination therapy in rheumatoid arthritis. Rheumatology 2004;43: Gonzalez-Alvaro I, Carmona L, Balsa A et al. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003;30: Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology 2002;41: Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists DMARD preferences for rheumatoid arthritis. Rheumatology 2004;43: Wolfe F, Albert DA, Pincus T. A survey of United States rheumatologists concerning effectiveness of diseasemodifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis. Arthritis Care Res 1998; 11: Maetzel A, Wong A, Strand V et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 2000;39: Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, J Rheumatol 1998;25: Hider SL, Silman A, Bunn D, Manning S, Symmons D, Lunt M. Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis 2006;65:
5 First line DMARD choice in early RA 18 Nandi P, Kingsley GH, Scott DL. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis. Curr Opin Rheumatol 2008;20: Kremers HM, Nicola P, Crowson CS, O Fallon WM, Gabriel SE. Therapeutic strategies in rheumatoid arthritis over a 40-year period. J Rheumatol 2004;31: Fautrel B, Guillemin F, Meyer O et al. Stratégies Thérapeutiques dans La Polyarthrite RhumatoIde Working Group; Club Rhumatismes et Inflammation; French Society of Rheumatology. Choice of second-line diseasemodifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists preferences. Arthritis Rheum 2009;61:
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study
RHEUMATOLOGY Rheumatology 2011;50:1106 1110 doi:10.1093/rheumatology/keq424 Advance Access publication 21 January 2011 Concise report The long-term impact of early treatment of rheumatoid arthritis on
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationDaniel F McWilliams 1*, Patrick D W Kiely 2, Adam Young 3 and David A Walsh 1,4
McWilliams et al. BMC Musculoskeletal Disorders 2013, 14:153 RESEARCH ARTICLE Open Access Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis:
More informationSupplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte
More informationJ. van Aken* H. van Dongen* S. le Cessie F.C. Breedveld T.W.J. Huizinga. * both authors contributed equally
CHAPTER Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study J. van Aken* H. van
More informationThis is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors..
This is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/118272/ Version: Accepted
More informationRheumatoid arthritis in adults: diagnosis and management
National Institute for Health and Care Excellence Consultation Rheumatoid arthritis in adults: diagnosis and management Evidence review F DMARDs NICE guideline CG79 Intervention evidence review January
More informationFatigue in rheumatoid arthritis reflects pain, not disease activity
Rheumatology 2006;45:885 889 Advance Access publication 31 January 2006 doi:10.1093/rheumatology/kel021 Concise Report Fatigue in rheumatoid arthritis reflects pain, not disease activity L. C. Pollard,
More informationOpen Access NY, USA. Keywords: HAQ, early RA, disease activity, DAS, cohort, correlation, longitudinal.
Send Orders for Reprints to reprints@benthamscience.net 58 The Open Rheumatology Journal, 2013, 7, 58-63 Open Access The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationV. P. K. Nell 1, K. P. Machold 1, G. Eberl 2, T. A. Stamm 1, M. Uffmann 3 and J. S. Smolen 1,2
Rheumatology 2004;43:906 914 Advance Access publication 27 April 2004 Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid
More informationRelative effect (95% CI) RR LOW 2,3 due to indirectness, imprecision. RR 1.45 (0.43 to 4.84) due to indirectness, imprecision. (0.18 to 20.
Appendix: Evidence Reports Question In patients with early RA with moderate or high disease activity, who are DMARD-naive, what is the impact of combination double DMARD therapy vs. mono-dmard therapy
More informationFaith Matcham, Sam Norton, David L Scott, Sophia Steer, Matthew Hotopf FA I T H M AT C H A M P H D S T U D E N T,
The impact of baseline and persistent symptoms of depression and anxiety on long-term physical health outcomes and response to treatment in Rheumatoid Arthritis Faith Matcham, Sam Norton, David L Scott,
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationA non-inferiority trial of an attenuated combination strategy ( COBRA-light ) compared to the original COBRA strategy: clinical results after 26 weeks
2 A non-inferiority trial of an attenuated combination strategy ( COBRA-light ) compared to the original COBRA strategy: clinical results after 26 weeks Debby den Uyl*, Marieke M. ter Wee*; Maarten Boers,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationCitation for final published version:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/97756/ This is the author s version of a work that was submitted to / accepted
More informationGenetic variation in FOXO3 is associated with reductions in inflammation and disease activity in inflammatory polyarthritis
Genetic variation in FOXO3 is associated with reductions in inflammation and disease activity in inflammatory polyarthritis Sebastien Viatte 1, James C. Lee 3,4, Bo Fu 1,5, Marion Espéli 6, Mark Lunt 7,
More informationSimilar clinical outcomes in rheumatoid arthritis with more versus
Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics T. Sokka 1, G. Haugeberg 2,3, J. Asikainen 1, I.J.
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationThe provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion
RHEUMATOLOGY Rheumatology 2012;51:1076 1080 doi:10.1093/rheumatology/ker425 Advance Access publication 1 February 2012 CLINICAL SCIENCE Concise report The provisional ACR/EULAR definition of remission
More informationRecommendations for RA management: what has changed?
The 2016 Update of the EULAR Recommendations for RA management: what has changed? Baltics Rheumatology Conference Vilnius, September 21-22 Prof. Diego Kyburz University Hospital of Basel Switzerland Multiple
More informationDrug combinations with methotrexate to treat rheumatoid arthritis
Drug combinations with methotrexate to treat rheumatoid arthritis T. Rath 1,2 and A. Rubbert 1 1 Department of Internal Medicine I, 2 Institute for Health Economics and Clinical Epidemiology, University
More informationIndividual Patient Characteristics Are There Differences in Responsiveness: Or How to Characterize Patients for Pivotal Trials
Individual Patient Characteristics Are There Differences in Responsiveness: Or How to Characterize Patients for Pivotal Trials Lee S. Simon, MD SDG LLC Cambridge, MA Consulting Affinergy Astrazeneca Abraxxis
More informationTreatment of early rheumatoid arthritis
REVIEW Treatment of early rheumatoid arthritis Karim Raza, Mike Salmon & Christopher D Buckley Author for correspondence University of Birmingham, Division of Immunity and Infection, Institute of Biomedical
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/24405 holds various files of this Leiden University dissertation. Author: Wevers- de Boer, Kirsten Vera Caroline Title: Improving disease outcomes in early
More information10/28/2013. Disclosures. Objectives. Background. Study Design. Key Inclusion Criteria
Randomization (1:1:1:1) /28/13 Tocilizumab in Combination Therapy and Monotherapy Versus Methotrexate in Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes
More informationUtility of disease modifying antirheumatic drugs in sawtooth strategy. A prospective study of early rheumatoid arthritis patients up to 15 years
68 Ann Rheum Dis 999;58:68 622 EXTENDED REPORTS Department of Medicine, Jyväskylä Central Hospital, Keskussairaalantie 9, FIN 462 Jyväskylä, Finland Correspondence to: Dr T Sokka. Accepted for publication
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationRheumatoid Arthritis. Ajay Bhatia Rheumatology Consultant Hillingdon Hospital
Rheumatoid Arthritis Ajay Bhatia Rheumatology Consultant Hillingdon Hospital ajay.bhatia@thh.nhs.uk Rheumatoid Arthritis When to refer to secondary care? Why early referral is beneficial for the patient?
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationR heumatoid arthritis (RA) is a chronic autoimmune
274 EXTENDED REPORT Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis J van Aken, L R Lard, S le Cessie, J M W Hazes, F
More informationF or the management of rheumatoid arthritis, there is
1294 EXTENDED REPORT Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial J Fransen, H Bernelot Moens, I
More informationR heumatoid arthritis (RA) is a chronic autoimmune
274 EXTENDED REPORT Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis J van Aken, L R Lard, S le Cessie, J M W Hazes, F
More informationConcordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent
Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent Michela Frendo, John Paul Caruana Galizia, Andrew A Borg Abstract Aims:
More informationAccess from the University of Nottingham repository: McWilliams--work_disability.pdf
McWilliams, Daniel F. and Varughese, Sneha and Young, Adam and Kiely, Patrick D. and Walsh, David A. (2013) Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort. Rheumatology,
More informationCombination therapy in. rheumatoid arthritis
Chapter 2 Combination therapy in rheumatoid arthritis YPM Goekoop CF Allaart FC Breedveld BAC Dijkmans Curr Opin Rheumatol 2001;13:177-83. ABSTRACT It has become clear that early suppression of rheumatoid
More informationORIGINAL ARTICLE DANIEL E. FURST, 1 AILEEN L. PANGAN, 2 LESLIE R. HARROLD, 3 HONG CHANG, 4 GEORGE REED, 3 JOEL M. KREMER, 5 AND JEFFREY D.
Arthritis Care & Research Vol. 63, No. 6, June 2011, pp 856 864 DOI 10.1002/acr.20452 2011, American College of Rheumatology ORIGINAL ARTICLE Greater Likelihood of Remission in Rheumatoid Arthritis Patients
More informationT raditional disease modifying antirheumatic drugs
944 EXTENDED REPORT Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study D Aletaha, T Stamm, T Kapral, G Eberl,
More informationAccess from the University of Nottingham repository:
McWilliams, Daniel F. and Zhang, Weiya and Mansell, Josephine S. and Kiely, Patrick D.W. and Young, Adam and Walsh, David A. (2012) Predictors of change in bodily pain in early rheumatoid arthritis: an
More informationBenefit/risk of combination therapies
Benefit/risk of combination therapies D. Zerkak, M. Dougados Rheumatology B Department, Cochin Hospital, René Descartes University, Paris, France. Djamila Zerkak, MD; Maxime Dougados, MD. Please address
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20644 holds various files of this Leiden University dissertation. Author: Klarenbeek, Naomi Bertine Title: Targeted treatment in early rheumatoid arthritis
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38506 holds various files of this Leiden University dissertation. Author: Nies, Jessica Annemarie Bernadette van Title: Early identification of rheumatoid
More informationChapter 4. Advances in Rheumatology 2004 volume 2
Chapter 4 Sustained remission in a cohort of patients with rheumatoid arthritis: association with absence of IgM rheumatoid factor and absence of anti-ccp antibodies. Advances in Rheumatology 2004 volume
More informationThe new ACR/EULAR remission criteria: rationale for developing new criteria for remission
RHEUMATOLOGY Rheumatology 2012;51:vi16 vi20 doi:10.1093/rheumatology/kes281 The new ACR/EULAR remission criteria: rationale for developing new criteria for remission Vivian P. Bykerk 1,2 and Elena M. Massarotti
More informationThe use of methotrexate in rheumatological conditions A review of the evidence. Maureen Cox January 2009
The use of methotrexate in rheumatological conditions A review of the evidence Maureen Cox January 2009 Visser et al Multinational evidence based recommendations for the use of methotrexate in rheumatic
More informationMeta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis
Jansen et al. BMC Musculoskeletal Disorders (2016) 17:348 DOI 10.1186/s12891-016-1195-4 RESEARCH ARTICLE Open Access Meta-analysis of long-term joint structural deterioration in minimally treated patients
More informationM. Schoels 1, F. Alasti 2, J. S. Smolen 1,2 and D. Aletaha 2*
Schoels et al. Arthritis Research & Therapy (2017) 19:155 DOI 10.1186/s13075-017-1346-5 RESEARCH ARTICLE Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28)
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationCorrespondence should be addressed to Martin J. Bergman;
Autoimmune Diseases Volume 2013, Article ID 367190, 7 pages http://dx.doi.org/10.1155/2013/367190 Research Article Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive
More informationPatient Outcomes in Rheumatoid Arthritis
Patient Outcomes in Rheumatoid Arthritis The impact of rheumatoid arthritis on patients quality of life A small qualitative study involving 25 patients with rheumatoid arthritis in Sweden looked at the
More informationIs Methotrexate A Disease Modifying Agent In Psoriatic Arthritis?
Disclosure Statement Is Methotrexate A Disease Modifying Agent In Psoriatic Arthritis? Gabrielle H Kingsley Consultant and Reader in Rheumatology King s College London Lewisham Healthcare NHS Trust Dr
More informationFactors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study
Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study C. Lukas 1, F. Guillemin 2, R. Landewé 3, D. van der Heijde 4, I. Logeart 5, B. Fautrel 6, J.P.
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationThis is the Accepted Version of a paper published in the journal Arthritis Care & Research:
ResearchOnline@JCU This is the Accepted Version of a paper published in the journal Arthritis Care & Research: Cummins, Lisa L., Vangaveti, Venkat, and Roberts, Lynden J. (2015) A Prioritisation Tool for
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationSuperior Efficacy of Combination Therapy for Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 52, No. 10, October 2005, pp 2975 2983 DOI 10.1002/art.21293 2005, American College of Rheumatology REVIEW Superior Efficacy of Combination Therapy for Rheumatoid Arthritis
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationCLINICAL COURSE AND REMISSION RATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RELATIONSHIP TO OUTCOME AFTER 5 YEARS
British Journal of Rheumatology 1998;37:1324 1329 CLINICAL COURSE AND REMISSION RATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RELATIONSHIP TO OUTCOME AFTER 5 YEARS K. EBERHARDT and E. FEX* Department
More informationBringing the clinical experience with anakinra to the patient
Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen
More informationHILAL MARADIT-KREMERS, PAULO J. NICOLA, CYNTHIA S. CROWSON, W. MICHAEL O FALLON, and SHERINE E. GABRIEL
Patient, Disease, and Therapy-Related Factors That Influence Discontinuation of Disease-Modifying Antirheumatic Drugs: A Population-Based Incidence Cohort of Patients with Rheumatoid Arthritis HILAL MARADIT-KREMERS,
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationCharacteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
Rheumatol Ther (2015) 2:85 96 DOI 10.1007/s40744-015-0008-9 ORIGINAL RESEARCH Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry
More informationReview. Margaret Har Yin Ma 1, Andrew P Cope 2 & David L Scott 1,2
Review Safety of combination therapies in early rheumatoid arthritis: a systematic comparison between antirheumatic drugs and TNF inhibitors with methotrexate We evaluated the frequency and type of adverse
More informationRecent data suggest that early therapy and achieving
116 Bulletin of the NYU Hospital for Joint Diseases 2011;69(2):116-21 A Quantitative Approach to Early Rheumatoid Arthritis Tom W.J. Huizinga, M.D., Ph.D., and Annette van der Helm-van Mil, M.D., Ph.D.
More informationEffectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials
Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials K. Martin 1, F. Bentaberry 2, C. Dumoulin 2, J. Dehais 2, F. Haramburu 1, B. Bégaud
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
More informationNATURAL REMISSION IN INFLAMMATORY POLYARTHRITIS: ISSUES OF DEFINITION AND PREDICTION
British Journal of Rheumatology 1996;3S:1096-l 100 NATURAL REMISSION IN INFLAMMATORY POLYARTHRITIS: ISSUES OF DEFINITION AND PREDICTION B. J. HARRISON, D. P. M. SYMMONS, P. BRENNAN, E. M. BARRETT* and
More informationPharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol)
Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol) Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationGlucocorticoid treatment in early rheumatoid arthritis
Glucocorticoid treatment in early rheumatoid arthritis D. Krause 1, R. Rau 2, J. Braun 3 1 Internistische und Rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, and Abteilung für Medizinische Informatik,
More informationCross-validation of a clinical pharmacogenetic model to predict the efficacy of MTX monotherapy in established
Chapter 5: Cross-validation of a clinical pharmacogenetic model to predict the efficacy of MTX monotherapy in established RA Jaap Fransen 1, Wouter M. Kooloos 2, Judith AM Wessels 2, Tom WJ Huizinga 3,
More informationR heumatoid arthritis is a chronic inflammatory disease with
1443 EXTENDED REPORT Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationCorresponding author: Daniel McWilliams, Arthritis Research UK Pain Centre, Academic
Erosive and osteoarthritic structural progression in early rheumatoid arthritis Daniel F McWilliams 1,2, Michelle Marshall 3, Keeranur Jayakumar 4, Sally Doherty 2, Michael Doherty 1,2, Weiya Zhang 1,2,
More informationG. Poór for the Leflunomide Multinational Study Group and V. Strand 1
Rheumatology 2004;43:744 749 Advance Access publication 16 March 2004 Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind,
More informationLearned helplessness predicts functional disability, pain and fatigue in patients with recent-onset inflammatory polyarthritis
RHEUMATOLOGY Rheumatology 2013;52:1233 1238 doi:10.1093/rheumatology/kes434 Advance Access publication 18 February 2013 Original article Learned helplessness predicts functional disability, pain and fatigue
More informationThe BeSt way of withdrawing biologic agents
The BeSt way of withdrawing biologic agents C.F. Allaart 1, W.F. Lems 2, T.W.J. Huizinga 1 1 Department of Rheumatology, Leiden University Medical Center, Leiden; 2 Department of Rheumatology, Free University
More informationNICE DECISION SUPPORT UNIT
SEQUENTIAL TNF-α INHIBITORS AND NON BIOLOGIC DMARDS ANALYSIS OF THE NATIONAL DATABANK FOR RHEUMATIC DISEASES. NICE DECISION SUPPORT UNIT Allan Wailoo School of Health and Related Research, University of
More informationABSTRACT. Keywords: Africa; Efficacy; Etanercept; Maintenance therapy; Middle East; Rheumatoid arthritis ORIGINAL RESEARCH
Rheumatol Ther (2018) 5:149 158 https://doi.org/10.1007/s40744-018-0094-6 ORIGINAL RESEARCH Maintenance of Remission with Etanercept DMARD Combination Therapy Compared with DMARDs Alone in African and
More informationA cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M
A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets
More informationThe medical treatment of rheumatoid arthritis has been dramatically improved with the
DOI: 10.5124/jkma.2010.53.10.871 pissn: 1975-8456 eissn: 2093-5951 http://jkma.org Focused Issue of This Month Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease
More informationHorizon Scanning Research & Intelligence Centre. Baricitinib for moderate to severe rheumatoid arthritis. May 2015 SUMMARY NIHR HSRIC ID: 5270
May 2015 Horizon Scanning Research & Intelligence Centre Baricitinib for moderate to severe rheumatoid arthritis SUMMARY NIHR HSRIC ID: 5270 This briefing is based on information available at the time
More informationORIGINAL ARTICLE R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 INTRODUCTION
Arthritis Care & Research Vol. 63, No. 1, January 2011, pp 128 134 DOI 10.1002/acr.20331 2011, American College of Rheumatology ORIGINAL ARTICLE American College of Rheumatology Hybrid Analysis of Certolizumab
More informationI nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide
I nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide Pierluigi Macchioni Struttura Complessa di Reumatologia, Ospedale di Reggio Emilia Topics 1987 ACR classification criteria for RA
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationG Wells, 1 J-C Becker, 2 J Teng, 2 M Dougados, 3 M Schiff, 4 J Smolen, 5 D Aletaha, 6 P L C M van Riel 7. Extended report
1 Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; 2 Bristol-Myers Squibb, Princeton, New Jersey, USA; 3 Paris-Descartes University, Medicine Faculty and UPRES-EA
More informationOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
RHEUMATOLOGY Rheumatology 2012;51:v12 v21 doi:10.1093/rheumatology/kes111 Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs Karel
More informationOptimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
Mian et al. Arthritis Research & Therapy (2016) 18:142 DOI 10.1186/s13075-016-1028-8 RESEARCH ARTICLE Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction
More informationPerspective. Combination therapy in rheumatoid arthritis: always the best option? Yasmin Bata1 & Yusuf Yazici*1
Combination therapy in rheumatoid arthritis: always the best option? One of the major developments in the treatment of rheumatoid arthritis over the last decade and a half has been the realization that
More informationNon-commercial use only
Reumatismo, 2016; 68 (2): 90-96 Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study K.T. Koh 1, C.L. Teh 2,
More informationIntegrating Quality Measures for RA into Your Practice: Optimizing Patient Care Using Your Own Data
Integrating Quality Measures for RA into Your Practice: Optimizing Patient Care Using Your Own Data Robin K. Dore, MD Clinical Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles,
More informationPRECISION MEDICINE: MAXIMISING TREATMENT BENEFIT FOR RHEUMATOID ARTHRITIS PATIENTS
PRECISION MEDICINE: MAXIMISING TREATMENT BENEFIT FOR RHEUMATOID ARTHRITIS PATIENTS This symposium took place on 9 th June 2016 as part of the European League Against Rheumatism (EULAR) Congress 2016 in
More informationK. Laas 1, R. Peltomaa 1, K. Puolakka 2, H. Kautiainen 3, M. Leirisalo-Repo 1
Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice K. Laas 1, R. Peltomaa 1, K. Puolakka 2, H.
More informationO ver many decades disease modifying antirheumatic
63 CONCISE REPORT Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years D Aletaha,
More informationEfficacy of prednisone 1 4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial
Efficacy of prednisone 1 4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial T Pincus, 1 C J Swearingen, 2 G Luta, 3 T Sokka 4 Extended
More informationComparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More information